QUOTE AND NEWS
SeekingAlpha  Aug 2  Comment 
Motley Fool  Jul 26  Comment 
The executive behind the most commonly used Alzheimer's drug is working on a follow-up that will be used in combination.
JCN Network  Jul 26  Comment 
TOKYO, Jul 26, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent...
JCN Network  Jul 4  Comment 
TOKYO, Jul 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that Wellness Open Living Labs. LLC, co-founded by Eisai, and Osaka City University have concluded a basic collaboration agreement aimed at solving health science-related...
JCN Network  Jun 28  Comment 
TOKYO, Jun 28, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series...
JCN Network  Jun 27  Comment 
TOKYO, Jun 27, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in...
JCN Network  Jun 23  Comment 
TOKYO, Jun 23, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the...
JCN Network  Jun 5  Comment 
TOKYO, Jun 5, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate (product...
FiercePharma  Jun 4  Comment 
Bayer and its stalwart Nexavar have had the first-line liver cancer field to themselves for years. But Eisai is doing its best to change that.
JCN Network  May 31  Comment 
TOKYO, May 31, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts...





You may also be interested in articles related to Eisai Co. Ltd. (ESALY):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki